CASIA OpenIR  > 中国科学院分子影像重点实验室
Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future
Cheng, Zhongquan1,2; Du, Yang2,3; Yu, Leyi1; Yuan, Zhu1; Tian, Jie2,3,4,5
Source PublicationMOLECULAR IMAGING AND BIOLOGY
ISSN1536-1632
2022-01-31
Pages16
Corresponding AuthorDu, Yang(yang.du@ia.ac.cn) ; Tian, Jie(tian@ieee.org)
AbstractWith the application of mono-immunotherapy in cancer, particularly immune checkpoint inhibitors, improved outcomes have been achieved. However, there are several limitations to immunotherapy, such as a poor response to the drugs, immune resistance, and immune-related adverse events. In recent years, studies of preclinical animal models and clinical trials have demonstrated that immune checkpoint inhibitors for breast cancer can significantly prolong the overall survival and quality of patients' lives. Meanwhile, combined immune checkpoint inhibitor treatment has attracted researchers' attention and showed great potential in the comprehensive treatment of breast cancer patients. Additionally, noninvasive imaging enables physicians to predict response to combined immunotherapeutic drugs, achieve treatment efficacy, and lead to better clinical management. Herein, we review the background of combined immune checkpoint inhibitor therapy and summarize its targeted imaging as well as progress in noninvasive imaging aimed at evaluating therapeutic outcomes. Finally, we describe several factors that may influence the outcome of this combined immunotherapy, the future direction of medical imaging, and the potential application of artificial intelligence in breast cancer. With further development of noninvasive imaging for the guidance of combined immune checkpoint inhibitors, cures for this disease may be achieved.
KeywordNoninvasive imaging Immune checkpoint inhibitor Combined immunotherapy Breast cancer
DOI10.1007/s11307-021-01688-9
WOS KeywordNEOADJUVANT CHEMOTHERAPY ; ADJUVANT IMMUNOTHERAPY ; COMBINATION ; BLOCKADE ; THERAPY ; CHALLENGES ; BIOMARKERS ; EFFICACY ; CTLA-4 ; TRASTUZUMAB
Indexed BySCI
Language英语
Funding ProjectBeijing Natural Science Foundation[7212207] ; National Natural Science Foundation of China[62027901] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[91859119] ; National Natural Science Foundation of China[61671449] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[61901472] ; National Public Welfare Basic Scientific Research Program of Chinese Academy of Medical Sciences[2018PT32003] ; National Public Welfare Basic Scientific Research Program of Chinese Academy of Medical Sciences[2017PT32004] ; National Key R&D Program of China[2018YFC0910602] ; National Key R&D Program of China[2017YFA0205200] ; National Key R&D Program of China[2017YFA0700401] ; National Key R&D Program of China[2016YFA0100902] ; National Key R&D Program of China[2016YFC0103702] ; natural science foundation of beijing municipality[62027901] ; natural science foundation of beijing municipality[81871514] ; natural science foundation of beijing municipality[81227901] ; natural science foundation of beijing municipality[81470083] ; natural science foundation of beijing municipality[91859119] ; natural science foundation of beijing municipality[61671449] ; natural science foundation of beijing municipality[81527805] ; natural science foundation of beijing municipality[61901472]
Funding OrganizationBeijing Natural Science Foundation ; National Natural Science Foundation of China ; National Public Welfare Basic Scientific Research Program of Chinese Academy of Medical Sciences ; National Key R&D Program of China ; natural science foundation of beijing municipality
WOS Research AreaRadiology, Nuclear Medicine & Medical Imaging
WOS SubjectRadiology, Nuclear Medicine & Medical Imaging
WOS IDWOS:000750274000001
PublisherSPRINGER
Citation statistics
Cited Times:1[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/47368
Collection中国科学院分子影像重点实验室
Corresponding AuthorDu, Yang; Tian, Jie
Affiliation1.Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing 100050, Peoples R China
2.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Key Lab Mol Imaging,State Key Lab Management & Co, Beijing 100190, Peoples R China
3.Univ Chinese Acad Sci, Beijing 100080, Peoples R China
4.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med Sci & Engn, Beijing 100191, Peoples R China
5.Xidian Univ, Sch Life Sci & Technol, Xian 710071, Shaanxi, Peoples R China
First Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Corresponding Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Recommended Citation
GB/T 7714
Cheng, Zhongquan,Du, Yang,Yu, Leyi,et al. Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future[J]. MOLECULAR IMAGING AND BIOLOGY,2022:16.
APA Cheng, Zhongquan,Du, Yang,Yu, Leyi,Yuan, Zhu,&Tian, Jie.(2022).Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future.MOLECULAR IMAGING AND BIOLOGY,16.
MLA Cheng, Zhongquan,et al."Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future".MOLECULAR IMAGING AND BIOLOGY (2022):16.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Cheng, Zhongquan]'s Articles
[Du, Yang]'s Articles
[Yu, Leyi]'s Articles
Baidu academic
Similar articles in Baidu academic
[Cheng, Zhongquan]'s Articles
[Du, Yang]'s Articles
[Yu, Leyi]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Cheng, Zhongquan]'s Articles
[Du, Yang]'s Articles
[Yu, Leyi]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.